Fig. 4.
In vivo activity of liposomal Cu(DDC)2 in animals bearing Pt resistant A2780-CP tumours. 1 × 106 A2780-CP cells were inoculated sc into immune-compromised NRG mice which were subsequently treated intravenously with vehicle (SH buffer), CuSO4-liposomes (1.7 mg/kg copper, 50 mg/kg lipid), and Cu(DDC)2 liposomes (8 mg/kg Cu(DDC)2 and 50 mg/kg lipid) using a 3 x per week for 2 weeks dosing schedule. Mean tumour volume was determined on day 18 (the humane endpoint for vehicle treated animals). Data represents the mean ± SEM (n = 7). * indicates statistical difference (p < 0.05)